PPARA and type 2 diabetes mellitus: In recent decades, several clinical trials demonstrated the beneficial effects of fenofibrate, a PPARα agonist, on type 2 diabetic patients, including decreases in creatinine clearance and estimated glomerular filtration rate (eGFR) (Forsblom et al., 2010; Ismail-Beigi et al., 2010; Wright and Dodson, 2011).